HP OnGuard siRNA Design from QIAGEN is an upgrade to the HiPerformance siRNA Design Algorithm. It uses advances in the knowledge of the RNAi mechanism to reduce the risk of off-target effects and ...
New funding led by Goldcrest Capital and Godfrey Capital to advance lead candidate JUN_01 for type 2 diabetes and obesity to first-in-human studies JUN_01 would be the first ever candidate to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results